Directors' College 2023
Jackie Liu
Partner, Morrison & Foerster LLP; Director, CEVA, Inc.
Jackie Liu is a strategist with 20 plus years of experience representing boards and management on corporate governance, public companies and high-stake M&A matters. She is a member of the Board of Directors of CEVA, Inc. (NASDAQ: CEVA), an Israeli-based, NASDAQ-listed, semiconductor company, as well as a senior corporate partner in the international firm of Morrison & Foerster LLP. Utilizing her language skills and cultural affinity, she also represents well-established Chinese companies on strategic matters relating to their U.S. operations and U.S. companies in setting up joint ventures and other partnerships with Chinese companies. For a number of years, Ms. Liu co-chaired her Firm’s Global Corporate Department of over 400 attorneys where she was responsible for the strategic direction of the corporate practice globally, as well as corporate partner and associate recruitment, integration, retention and professional development.
Ms. Liu regularly advises companies on corporate governance matters, including board and committee leadership and organization, board and CEO transitions, succession planning, investor relations, DE&I, ESG, director and officer fiduciary duties, and board “best practices.” Ms. Liu has been a trusted advisor to a number of companies with whom she has worked with for over 20 years and provides big picture, critical, value-adding strategic advice. Her public company board experience provides unique perspectives on corporate governance engagements.
Ms. Liu has represented public and private companies in mergers and acquisitions, from small asset acquisitions and divestitures, founder-driven sales, and talent acquisitions to multibillion-dollar transactions such as SOFTBANK’s acquisition of Sprint and Intel’s acquisition of McAfee.
Furthermore, Ms. Liu has been involved in complex cross-border transactions in Asia, Australia, and Europe, including NCR Corporation’s acquisition of Israel-based Retalix, Intel’s minority stake in Netherlands-based ASML, Japan-based Santen Pharmaceutical in its joint venture with Verily, sale of Israel-based Syneron to APAX, PRC-based MicroPort Scientific’s acquisition of the orthopedics business of Wright Medical, and McKesson’s acquisition of Israel-based Medcon.
Ms. Liu was born in Shanghai, China, and immigrated to the U.S. with her parents at a young age. She is fluent in Mandarin Chinese.
Related Sessions
© Stanford University. Stanford, California 94305.